Eight patients with aggressive nonHodgkins lymphoma treated with Kite Pharma Incs cancer drug lead candidate were in complete remission and four others in partial remission the company said Monday Shares surged  to  in recent afterhours trading well above their  debut but shy of the week high set on June  shortly after the companys initial public offering  The
  